NCT03552471View on ClinicalTrials.gov

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 12, 2018

Primary Completion Date

June 24, 2022

Study Completion Date

December 19, 2022

Conditions
BRCA1 Gene MutationBRCA2 Gene MutationFolate Receptor Alpha PositiveRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaRecurrent Uterine Serous CarcinomaRecurrent Uterine CarcinosarcomaPlatinum Resistant Ovarian Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Mirvetuximab Soravtansine

Given IV

OTHER

Pharmacokinetic Study

Correlative studies

DRUG

Rucaparib Camsylate

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors
All Listed Sponsors
collaborator

ImmunoGen, Inc.

INDUSTRY

collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT03552471 - Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter